Clinical Trials Browser

Terminated × Interventional × RG7388 × Clear all

NCT04029688 2024-12-20

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Phase 1/2 Terminated

38 enrolled 34 charts

CNSLymphoidOther hematologic neoplasm

Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03555149 2023-11-07

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

Phase 1/2 Terminated

96 enrolled 24 charts

Gastrointestinal

Colorectal Neoplasms

NCT02545283 2022-01-11

MIRROS

Phase 3 Terminated

447 enrolled 24 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03287245 2021-12-08

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Phase 2 Terminated

27 enrolled 28 charts

Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT03135262 2021-12-07

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Terminated

29 enrolled 18 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT03566485 2021-08-11

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Phase 1/2 Terminated

12 enrolled 13 charts

Breast Neoplasms

NCT02624986 2020-05-18

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

Phase 1/2 Terminated

25 enrolled 21 charts

Lymphoma, Non-Hodgkin